Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

New antibodies and antigens, 6/14

June 2014—The Binding Site has expanded its offering of clinical and research products to include a distinctive group of horseradish peroxidase conjugated sheep antibodies specific to human IgA, IgG, and IgM immunoglobulins and their fractional components.

POC devices, 6/14

June 2014—The Minivette POC testing devices from Sarstedt are for the collection, transfer, and subsequent dispensing of small capillary blood samples for point-of-care tests. Blood is collected via capillary action into the collection capillary, the sample is held securely during transfer, and then it is dispensed onto the test field or into a micro tube with a slight push of the opposing integral piston.

High-performance centrifuge, 6/14

June 2014—Avanti JXN-26 centrifuges from Beckman Coulter have an intuitive interface and advanced data management features, including the ability to track and manage centrifuge runs remotely using Mobile­Fuge, a mobile application for Apple iOS or Android devices.

Reusable sharps container, 5/14

December 2013—Rehrig Pacific’s SharpsTank reusable sharps container model TS has received FDA 510(k) clearance as a class II medical device. The SharpsTank model TS is a 4.9-gallon reusable container with an integrated hinged lid, restrictive mail chute, and flusher insert. The container is supplied to the customer fully assembled.

ConfirmMDx case study, 5/14

May 2014—Cancer test was used as part of a multidisciplinary approach to confirm prostate cancer diagnosis using a technique called transperineal mapping biopsy. The cancer lesions found using this method were not detected by five conventional biopsies.

Multilabel slide scanner, 5/14

May 2014—PerkinElmer launched the Lamina multilabel slide scanner at the USCAP 2014 Annual Meeting. The scanner is a high-throughput imaging system for research pathologists in a larger research facility to study protein expression and the relationships between disease markers in formalin-fixed, paraffin-embedded tissue sections.

Clarient adopts THxID-BRAF, 5/14

April 2014—BioMérieux’s molecular diagnostic test THxID-BRAF has been added to the offerings provided by Clarient, a GE Healthcare company.

Hsp70 ELISA kit, 5/14

May 2014—Enzo Life Sciences now offers the Amp’d HSP70 High Sensitivity ELISA Kit for detecting both baseline and upregulated levels of Hsp70 (Hsp72).

Insight Genetics and VICC partnership, 5/14

May 2014—Insight Genetics is collaborating with Vanderbilt-Ingram Cancer Center (VICC) to identify genetic markers that will help select the targeted therapeutics most effective for each triple-negative breast cancer patient.